BBS Nanotechnology is a privately held company focused on the generation of anti-cancer therapeutics and diagnostics and is a leader in the development of biocompatible, targeted cancer nanosystems for improved patient outcomes.
BBS Nanotechnology is entirely focused on making nanoencapsualtion technology a success. The project outlined in the proposal is therefore the absolute core activity of the company. Two workgroups help and complete together: the chemists prepare the nanosystems for different purposes the biologists control and test the particles and the continuous feedback allows the development of the most suitable delivery nanosystems.
We are developing a pipeline of novel therapeutic and diagnostic candidates, including differentiated programs in ovarian, breast, lung and rare cancers. BBS Nanotechnology’s proprietary platform couples proven cytotoxic oncology drugs with targeted encapsulation to generate high affinity binding to cancer cells, brings cytotoxic and diagnostic agents to cancer cells while avoiding healthy cells and overcomes the limitations of prior nanopartical technologies.
The controlled flexibility of BBS’ unique chemistry allows for the selection of optimally targeted nanoparticles to achieve high affinity binding, stability, efficacy and manufacturability.
Dr. Eszter Prépost
Dr. Eszter Prépost, CEO. After graduating at the Medical University of Pécs (Hungary) Eszter has started as a Clinical Research Associate at Sanofi-Aventis. After gaining knowledge on various therapeutic areas she moved on to set up the local affiliate of an international Contract Research Organization (Averion International) as a general manager at the same time leading the local team, providing project management as well as client liaison and business development services. She gained further insight on clinical research, particularly on cross-functional and international collaborations at a multinational pharma company (Merck Sharp & Dohme) as an associate director where she was exposed to tasks on a regional scale.